Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.


29 Sep 2019


Poster Display session 2


Tumour Site

Neuroendocrine Neoplasms


Rita Conde


Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256


R.S. Conde1, S.C. Ferreira1, S. Esteves2, I. Claro3, A. Moreira1, M.T. Marques1, M.B. Goncalves1

Author affiliations

  • 1 Serviço De Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), 1099-023 - Lisbon/PT
  • 2 Unidade De Investigação Clínica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), 1099-023 - Lisbon/PT
  • 3 Serviço De Gastroenterologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), 1099-023 - Lisbon/PT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4175


EP-HG-NEC are rare malignancies with poor prognosis, mainly from the gastrointestinal (GI) tract, although they may originate anywhere in the body due to the wide distribution of the neuroendocrine system. Platinum plus etoposide regimen (PE) is standard of care. Our goal was to characterise EP-HG-NEC at our institute, evaluate primary tumor location as prognostic factor and the effectiveness of PE as first-line (1L) therapy.


Records of patients (pts) diagnosed with EP-HG-NEC at a Portuguese terciary cancer center were reviewed retrospectively (January 2000-March 2019).


Fifty-eight pts (52% males) identified: median (m) follow-up was 21 months (M) (range: 4-43); at diagnosis, m age was 61 years (range 30-85), 81% had ECOG performance status of 0-1, 83% were symptomatic, 64% had metastatic disease (70% with liver metastasis), 48% had Ki67 above 55%. Primary tumor location was GI in 27 pts (33% Esophagus, 19% colorectal, 15% pancreas), unknown (CUP) in 24 pts and genitourinary (GU) in 7 pts. For all EP-HG-NEC, m overall survival (OS) was 15,7M. Pts with CUP seemed to have a worse prognosis (mOS=8,5M), whereas GU and GI had a similar prognosis (mOS=19,2 and 18,7M, respectively) (p = 0.357).Thirty-nine pts (67%) got PE, 7 pts received a different chemotherapy (ChT) regimen and 9 pts got best supportive care (BSC) only. mPFS was 4,6M for PE group and 7,3M for other ChT regimen group (platinum alone, CAPTEM, 5FU-STZ) with no statistical significance (p = 0.547). mOS was 15,7M for PE group and 6,9M for BSC group (p = 0.54). With PE, 41% had grade 3 adverse events and no toxic deaths were reported. After 1L PE, 24 pts received a second L ChT, 50% with CAPTEM.


Considering the limited data available, this retrospective case series contributes to a better understanding of this entity. Primary tumor location tends to predict outcome. We hypothesised that delaying treatment initiation for CUP while searching for primary tumor might be related to worse outcomes. The outcomes of 1L PE suggest that other options might be needed as standard of care. EP-HG-NEC has prognostic heterogeneity, multi-center studies are needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.